Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK101 in Moderate to Severe Plaque Psoriasis
NCT04173637Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Dec 2019
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ebdarokimab in plaque psoriasis, sponsored by Akeso, Inc.. Started Dec 2019; status: completed.
02
Drugs
ebdarokimab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04173637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04173637.